Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
Efficacy of inactivated whole-virus and subunit vaccines in preventing HIV-2 infection in cynomolgus monkeys.
Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 11. Unique Identifier : AIDSLINE PRIM11/94191603 Putkonen P; Thorstensson R; Ghavamzadeh L; Gilljam G; Biberfeld G; Department of Immunology, National Bacteriological Laboratory,; Stockholm, Sweden.
Abstract:
The goal with this study was to compare the protective effect of vaccination of cynomolgus monkeys with a whole-virus vaccine and viral envelope glycoprotein subunit vaccine following challenge with homologous cell-free HIV-2. The challenge virus was grown on cynomolgus monkey PBMC. The challenge dose was 10 to 100 MID50 of HIV-2(SBL-6669). Challenged monkeys were monitored for signs of HIV-2 infection by virus isolation, HIV-2 specific antibody responses and by PCR assay. Whole inactivated HIV-2: A total of 23 cynomolgus monkeys were immunized with whole inactivated HIV-2 preparations formulated with five different adjuvant formulations (Incomplete Freund's adjuvant, Alum, Ribi, MDP and Iscoms). After i.v. challenge 17 of 18 controls and 4 of 4 monkeys vaccinated with whole virus vaccine in Alum became infected. However protection was achieved in 2 of 2 monkeys receiving this vaccine with IFA, 4 of 9 given the vaccine with Ribi adjuvant and 1 of 4 given the vaccine with MDP adjuvant. Furthermore, 3 of 4 monkeys immunized five times with detergent-treated HIV-2(SBL-6669) in iscoms and then boosted twice with synthetic peptides representing a dominating neutralizing region of HIV-2 envelope glycoprotein were also protected against the homologous HIV-2 infection. Classical neutralization assay failed to show any correlation with protection. HIV-2 subunit vaccine: HIV-2(SBL-6669) gp 125 envelope was purified by affinity chromatography using Galantis Nevalis lectin. Five monkeys were immunized at 0, 2, 4, 6 and 9 months with HIV-2 gp 125 (35 micrograms/dose) in iscoms and another four monkeys received five immunizations of gp 125 (60 micrograms/dose) in Ribi adjuvant. The vaccinated monkeys along with four parallel control monkeys were challenged three weeks after the fifth immunization with 30 MID50 of homologous HIV-2. All controls were infected, but 2 of 5 monkeys vaccinated with gp 125 in iscoms and 2 of 4 monkeys immunized with gp 125 in Ribi were protected. Conclusion: These studies demonstrate that both an HIV-2 inactivated whole-virus vaccine and a viral envelope glycoprotein-based subunit vaccine can provide protection against challenge of homologous virus grown on simian cells.
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/*PREVENTION & CONTROL Animal AIDS Vaccines/*THERAPEUTIC USE Comparative Study Freund's Adjuvant HIV Antibodies/BLOOD HIV-2/*IMMUNOLOGY/ISOLATION & PURIF ISCOMs/THERAPEUTIC USE Macaca fascicularis Macromolecular Systems Polymerase Chain Reaction Vaccines, Inactivated/*THERAPEUTIC USE Viral Envelope Proteins/*IMMUNOLOGY ABSTRACT 940730
M9470915
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
